- Trump on the health care vote: ‘I hope that it’s going to all work out’ March 22, 2017
- Twisting arms for Obamacare repeal, Trump warns Republicans the voters are watching March 21, 2017
- Array BioPharma Announces Withdrawal of NDA for Binimetinib Monotherapy for the Treatment of NRAS-Mutant Melanoma March 18, 2017
- FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson’s Disease March 21, 2017
- FDA Approves Juvéderm Vollure XC for Correction of Facial Wrinkles and Folds in Adults March 20, 2017
- Study Says Drug Cuts Cholesterol and Reduces Heart Attacks, But It’s Not Cheap March 17, 2017
- Man killed after trying to grab soldier’s gun at Paris airport March 18, 2017
- Campaign heats up to make heroin-overdose reversal drug available everywhere March 18, 2017
- Who Really Needs Cholesterol and Blood Pressure Drugs March 17, 2017
- Absorb GT1 Bioresorbable Vascular Scaffold (BVS) by Abbott Vascular: Letter to Health Care Providers – FDA Investigating Increased Rate of Major Adverse Cardiac Events March 18, 2017
The Food and Drug Administration department approved of Alimta recently as an effective measure for treating malignant pleural mesothelioma – a rare form of carcinoma of the mesothelium lining (in the lungs or abdomen or heart) brought forth by asbestos exposure. It requires to be administered with Cisplatin, another medicine for treating cancer. Alimta blocks specific enzymes that accelerate the growth of the cancerous tumors. Thus, if someone thinks it to be a complete cure for malignant pleural mesothelioma, know that the drug just increases the median survival rate of cancer patients that Cisplatin alone has had provided all these years; it increased to 12.1 months per person on an average from the previous 9.3 months span.
Alimta is administered through the veins and is thus an intravenous drug. The frequency is one dose in about every 21 days. After 30 minutes of pushing Alimta, Cisplatin is infused after administering folic acid and vitamin B12 to the patient. This has been found to lower and at times, completely eliminate the side effects of Alimta. However, if you are pregnant or planning for pregnancy, stay away from the drug as it can harm substantially an embryo. The same is advised to patients
with renal disorders or the ones under non-steroidal anti-inflammatory drugs.
The most common side effects of Alimta are an upset stomach, nausea, vomiting, diarrhea, dropped platelets, leucocyte and erythrocyte count, infection, anemia, tiredness, sores in the face region, loss of appetite and rash. However, if preceded and succeeded with cortico-steroids (a steroid hormone produced by the adrenal cortex or synthesized; administered as drugs they decrease swelling and response to the body’s immune process), Alimta treatment does not give rise to any skin reaction. In order to ensure reaction free treatment, your doctor or
physician will conduct regular blood tests prior to and after Almita treatment.